Rebates for anti-anemia drugs draw response from FDA, CMS.
Martin
M
Sipkoff
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D014487:Centers for Medicare and Medicaid Services, U.S.; D016265:Conflict of Interest; D000068256:Darbepoetin alfa; D004345:Drug Industry / Q000191:economics*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use*; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008495:Medical Oncology / Q000191:economics*; D006278:Medicare; D009369:Neoplasms / Q000150:complications; D009398:Nephrology / Q000191:economics*; D011358:Product Surveillance, Postmarketing; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa